Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Accounts Payables (2022 - 2026)

HeartSciences filings provide 5 years of Accounts Payables readings, the most recent being $410727.0 for Q1 2026.

  • On a quarterly basis, Accounts Payables rose 1.4% to $410727.0 in Q1 2026 year-over-year; TTM through Jan 2026 was $410727.0, a 1.4% increase, with the full-year FY2025 number at $318661.0, down 28.9% from a year prior.
  • Accounts Payables hit $410727.0 in Q1 2026 for HeartSciences, up from $317390.0 in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $1.1 million in Q4 2023 to a low of $276848.0 in Q4 2024.
  • Median Accounts Payables over the past 5 years was $431629.5 (2024), compared with a mean of $527040.0.
  • Biggest five-year swings in Accounts Payables: skyrocketed 36.85% in 2023 and later plummeted 74.56% in 2024.
  • HeartSciences' Accounts Payables stood at $795266.0 in 2022, then skyrocketed by 36.85% to $1.1 million in 2023, then plummeted by 74.56% to $276848.0 in 2024, then increased by 14.64% to $317390.0 in 2025, then rose by 29.41% to $410727.0 in 2026.
  • The last three reported values for Accounts Payables were $410727.0 (Q1 2026), $317390.0 (Q4 2025), and $283225.0 (Q3 2025) per Business Quant data.